Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis

New England Journal of Medicine

Volumn 376, Issue 20, 2017, Pages 1921-1932

  Wechsler, M E ^a   Akuthota, P ^b,c   Jayne, D ^d   Khoury, P ^h   Klion, A ^h   Langford, C A ⁱ   Merkel, P A ^j   Moosig, F ^l   Specks, U ^m   Cid, M C ⁿ   Luqmani, R ^e   Brown, J ^f   Mallett, S ^f   Philipson, R ^g   Yancey, S W ^k   Steinfeld, J ^k   Weller, P F ^c   Gleich, G J ^o  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f GLAXOSMITHKLINE   (United Kingdom)

^g Trizell   (United Kingdom)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k GLAXOSMITHKLINE   (United States)

^l Rheumazentrum Schleswig Holstein Mitte   (Germany)

^m MAYO CLINIC   (United States)

ⁿ HOSPITAL CLÍNIC   (Spain)

^o UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MEPOLIZUMAB; PLACEBO; PREDNISOLONE; PREDNISONE; GLUCOCORTICOID; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ARTHRALGIA; ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHURG STRAUSS SYNDROME; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS; FEMALE; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; REMISSION; RHINOPHARYNGITIS; SINUSITIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; UPPER RESPIRATORY TRACT INFECTION; ADVERSE EFFECTS; CHURG-STRAUSS SYNDROME; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; EOSINOPHIL; IMMUNOLOGY; INTENTION TO TREAT ANALYSIS; LEUKOCYTE COUNT; MIDDLE AGED; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CHURG-STRAUSS SYNDROME; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EOSINOPHILS; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; INTENTION TO TREAT ANALYSIS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION;

EID: 85019805787     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1702079     Document Type: Article

References (34)

1. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26-37.
2. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951;27:277-301.
3. Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11.
4. Cottin V, Bel E, Bottero P, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J 2016;48:1429-41.
5. Akuthota P, Weller PF. Eosinophils and disease pathogenesis. Semin Hematol 2012;49:113-9.
6. Khoury P, Grayson PC, Klion AD. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol 2014;10:474-83.
7. Dunogué B, Pagnoux C, Guillevin L. Churg-Strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment. Semin Respir Crit Care Med 2011;32:298-309.
8. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016;75:1583-94.
9. Mahr A, Moosig F, Neumann T, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Curr Opin Rheumatol 2014;26:16-23.
10. Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013;65:270-81.
11. Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008;58:586-94.
12. Baldini C, Talarico R, Della Rossa A, Bombardieri S. Clinical manifestations and treatment of Churg-Strauss syndrome. Rheum Dis Clin North Am 2010;36:527-43.
13. Samson M, Puéchal X, Devilliers H, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun 2013;43:60-9.
14. Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 2016;75:952-7.
15. Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther 2011;33:1413-32.
16. Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci 2005;1051:121-31.
17. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84.
18. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9.
19. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189-97.
20. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-207.
21. Nair P, Pizzichini MMM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93.
22. Kahn JE, Grandpeix-Guyodo C, Marroun I, et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol 2010;125:267-70.
23. Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010;125:1336-43.
24. Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011;155:341-3.
25. Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 2015;26:545-53.
26. Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827-32.
27. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
28. Cloutier MM, Schatz M, Castro M, et al. Asthma outcomes: composite scores of asthma control. J Allergy Clin Immunol 2012;129:Suppl:S24-S33.
29. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-7.
30. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358:1215-28.
31. Annapureddy N, Elsallabi O, Baker J, Sreih AG. Patient-reported outcomes in ANCA-associated vasculitis: a comparison between Birmingham Vasculitis Activity Score and routine assessment of patient index data 3. Clin Rheumatol 2016;35:395-400.
32. Dejaco C, Oppl B, Monach P, et al. Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). PLoS One 2015;10(3):e0121737.
33. Grayson PC, Monach PA, Pagnoux C, et al. Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford) 2015;54:1351-9.
34. Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 2016;75:396-401.